User login
Key clinical point: Compared with Bruton tyrosine kinase inhibitors (BTKi) alone, BTKi + anti-CD20 monoclonal antibodies (mAb) demonstrated better efficacy in patients with untreated, relapsed, or refractory chronic lymphocytic leukemia (CLL) without causing safety concerns.
Major finding: The BTKi + anti-CD20 mAb therapy vs BTKi monotherapy group had significantly improved progression-free survival (hazard ratio 0.70; 95% CI 0.51-0.97), complete response rate (relative risk [RR] 2.03; 95% CI 1.01-4.06), and undetectable minimal residual disease rate (RR 6.43; 95% CI 3.54-11.67) and a similar risk for grade ≥3 adverse events (RR 1.08; 95% CI 0.80-1.45).
Study details: Findings are from a meta-analysis of 4 randomized controlled trials including 1056 patients who received a BTKi + anti-CD20 mAb or BTKi monotherapy for untreated, relapsed, or refractory CLL.
Disclosures: This study was supported by grants from the National Science and Technology Council in Taiwan and the industry-academia cooperation program. The authors declared no conflicts of interest.
Source: Nguyen TT et al. Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: A meta-analysis. Sci Rep. 2023;13:9775 (Jun 16). Doi: 10.1038/s41598-023-36279-x
Key clinical point: Compared with Bruton tyrosine kinase inhibitors (BTKi) alone, BTKi + anti-CD20 monoclonal antibodies (mAb) demonstrated better efficacy in patients with untreated, relapsed, or refractory chronic lymphocytic leukemia (CLL) without causing safety concerns.
Major finding: The BTKi + anti-CD20 mAb therapy vs BTKi monotherapy group had significantly improved progression-free survival (hazard ratio 0.70; 95% CI 0.51-0.97), complete response rate (relative risk [RR] 2.03; 95% CI 1.01-4.06), and undetectable minimal residual disease rate (RR 6.43; 95% CI 3.54-11.67) and a similar risk for grade ≥3 adverse events (RR 1.08; 95% CI 0.80-1.45).
Study details: Findings are from a meta-analysis of 4 randomized controlled trials including 1056 patients who received a BTKi + anti-CD20 mAb or BTKi monotherapy for untreated, relapsed, or refractory CLL.
Disclosures: This study was supported by grants from the National Science and Technology Council in Taiwan and the industry-academia cooperation program. The authors declared no conflicts of interest.
Source: Nguyen TT et al. Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: A meta-analysis. Sci Rep. 2023;13:9775 (Jun 16). Doi: 10.1038/s41598-023-36279-x
Key clinical point: Compared with Bruton tyrosine kinase inhibitors (BTKi) alone, BTKi + anti-CD20 monoclonal antibodies (mAb) demonstrated better efficacy in patients with untreated, relapsed, or refractory chronic lymphocytic leukemia (CLL) without causing safety concerns.
Major finding: The BTKi + anti-CD20 mAb therapy vs BTKi monotherapy group had significantly improved progression-free survival (hazard ratio 0.70; 95% CI 0.51-0.97), complete response rate (relative risk [RR] 2.03; 95% CI 1.01-4.06), and undetectable minimal residual disease rate (RR 6.43; 95% CI 3.54-11.67) and a similar risk for grade ≥3 adverse events (RR 1.08; 95% CI 0.80-1.45).
Study details: Findings are from a meta-analysis of 4 randomized controlled trials including 1056 patients who received a BTKi + anti-CD20 mAb or BTKi monotherapy for untreated, relapsed, or refractory CLL.
Disclosures: This study was supported by grants from the National Science and Technology Council in Taiwan and the industry-academia cooperation program. The authors declared no conflicts of interest.
Source: Nguyen TT et al. Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: A meta-analysis. Sci Rep. 2023;13:9775 (Jun 16). Doi: 10.1038/s41598-023-36279-x